KNSA
Kiniksa Pharmaceuticals Ltd
NASDAQ: KNSA · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$52.99
-1.60% today
Updated 2026-04-29
Market cap
$4.08B
P/E ratio
58.23
P/S ratio
6.02x
EPS (TTM)
$0.91
Dividend yield
—
52W range
$25 – $54
Volume
0.8M
Kiniksa Pharmaceuticals Ltd (KNSA) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | $56.47M | $47.49M | $321.96M | $254.53M | $349.46M | $232.80M | $459.67M | $526.32M | $580.55M |
| Cash & equivalents | $55.97M | $45.55M | $307.30M | $46.93M | $114.04M | $122.47M | $122.72M | $107.95M | $183.58M |
| Current assets | $56.33M | $47.10M | $313.75M | $241.63M | $333.25M | $196.45M | $243.06M | $276.30M | $331.80M |
| Total liabilities | $82.20M | $137.20M | $42.70M | $29.11M | $37.53M | $47.76M | $63.52M | $87.48M | $142.12M |
| Current liabilities | $2.30M | $17.43M | $42.55M | $27.83M | $31.85M | $44.82M | $47.07M | $63.67M | $100.62M |
| Long-term debt | — | — | — | — | — | — | — | — | — |
| Shareholder equity | $-25.73M | $-89.71M | $-194.22M | $225.42M | $311.94M | $185.04M | $396.15M | $438.84M | $438.44M |
| Retained earnings | $-26.13M | $-91.00M | $-194.22M | $-356.09M | $-517.47M | $-675.40M | $-492.03M | $-477.95M | $-521.14M |
| Accounts receivable | — | — | — | — | $0.00 | $3.98M | $20.32M | $21.27M | $41.72M |
| Inventory | — | — | — | — | $0.00 | $3.67M | $21.60M | $31.12M | $26.36M |
| Goodwill | — | — | — | — | — | — | — | — | — |